STING1 and cancer: Accordingly, several human STING agonists have been developed in recent years by academic and pharmaceutical industry laboratories (Ramanjulu et al., 2018; Chin et al., 2020; Pan et al., 2020), and clinical trials are underway to assess their efficacy against cancers in combination with immune checkpoint inhibitors (Le Naour et al., 2020).